Cisplatin + 5-fluorouracil (metastatic penile SCC, 1L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-CISPLATIN` `DRUG-5-FLUOROURACIL`

ID	`REG-CISPLATIN-5FU-PENILE`
Type	Regimen
Status	reviewed 2026-07-11 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-EAU-PENILE-2024`

Notes

STUB. Cisplatin + 5-FU is the classic doublet for metastatic/unresectable penile SCC per EAU guidelines, alongside TIP (REG-TIP-PENILE). No phase III RCT exists in this rare disease — evidence base is small retrospective/phase II series; regimen composition and general SCC-doublet dosing convention (analogous to head & neck / cervical / anal SCC cisplatin+5-FU protocols) drafted pending clinical co-lead signoff (CHARTER §6.1; dev-mode-exempted for draft merge). Choice between this doublet and TIP is MDT/fitness-based — see ALGO-PENILE-SCC-1L step 5.

Used By

Indication

IND-PENILE-SCC-METASTATIC-1L-CISPLATIN-5FU - IND-PENILE-SCC-METASTATIC-1L-CISPLATIN-5FU

Regimen

REG-TIP-PENILE - TIP (paclitaxel + ifosfamide + cisplatin, penile SCC)